These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18473796)

  • 1. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM; Salvador JA; Vasaitis TS; Njar VC
    Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
    Njar VC; Brodie AM
    Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP17 inhibitors for prostate cancer therapy.
    Vasaitis TS; Bruno RD; Njar VC
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
    Owen CP
    Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
    J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CYP17: established and novel approaches in prostate cancer.
    Yap TA; Carden CP; Attard G; de Bono JS
    Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
    Salvador JA; Pinto RM; Silvestre SM
    J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
    Clement OO; Freeman CM; Hartmann RW; Handratta VD; Vasaitis TS; Brodie AM; Njar VC
    J Med Chem; 2003 Jun; 46(12):2345-51. PubMed ID: 12773039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
    J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
    Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
    J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
    Hartmann RW; Ehmer PB; Haidar S; Hector M; Jose J; Klein CD; Seidel SB; Sergejew TF; Wachall BG; Wächter GA; Zhuang Y
    Arch Pharm (Weinheim); 2002 Apr; 335(4):119-28. PubMed ID: 12112031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
    Hu Q; Negri M; Olgen S; Hartmann RW
    ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP17A1: a biochemistry, chemistry, and clinical review.
    Porubek D
    Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling study of some inhibitors of 17,20-lyase, a component of the enzyme 17 alpha-hydroxylase/17,20-lyase: a novel approach.
    Ahmed S; Keane J
    Biochem Biophys Res Commun; 1998 Dec; 253(2):273-6. PubMed ID: 9878527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents.
    Wróbel TM; Rogova O; Andersen KL; Yadav R; Brixius-Anderko S; Scott EE; Olsen L; Jørgensen FS; Björkling F
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.